FDA Approves NAPROXEN — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. announced late Monday the approval of its Abbreviated New Drug Application, No. ANDA215776, for the oral formulation of Naproxen, triggering a green light for generic market entry in the United States. The launch is expected to intensify the ongoing price war for nonsteroidal anti-inflammatory drugs, creating additional competitive pressure on the existing brandedpain management market.